Danaher Corporation (DHR) Q3 FY2026 8-K Filings and Company Events
More for Danaher: Company index · Financial statements · 10-K and 10-Q summary
PeriodQ3 FY2026
Published
This page digests the material Form 8-K filings Danaher Corporation (DHR) has made over roughly the trailing five quarters: earnings releases, management and board changes, capital returns, financing, and governance actions. Each item cites the SEC accession number of the filing it came from. It is current through Q3 FY2026, the period ended 2026-09-25, as reported in the 10-Q filed with the SEC.
Filings that contain financial statements
- Form 8-K, October 21, 2026, accession 0000313616-26-000201 (Exhibit 99.1): consolidated condensed statement of earnings for the three and nine months ended September 25, 2026 (with September 26, 2025 comparatives), plus non-GAAP reconciliations and a free cash flow table. No balance sheet or cash flow statement. The release states that the complete financial statements are in the Form 10-Q (accession 0000313616-26-000199).
- Form 8-K, July 21, 2026, accession 0000313616-26-000163 (Exhibit 99.1): consolidated condensed statement of earnings for the three and six months ended June 26, 2026, plus reconciliations and free cash flow.
- Form 8-K, April 21, 2026, accession 0000313616-26-000109 (Exhibit 99.1): consolidated condensed statement of earnings for the three months ended March 27, 2026, plus reconciliations and free cash flow.
- Form 8-K, January 28, 2026, accession 0000313616-26-000004 (Exhibit 99.1): consolidated balance sheets, statements of earnings and statements of cash flows for the fourth quarter and year ended December 31, 2025.
Acquisition of Masimo (closed)
- February 17, 2026 (accession 0001193125-26-053124): Danaher announced it had signed a merger agreement dated February 16, 2026 to acquire all outstanding Masimo Corporation common stock for $180.00 per share in cash, through a merger of Mobius Merger Sub, Inc. into Masimo.
- April 17 and April 29, 2026 (accessions 0001193125-26-160383 and 0001193125-26-191608): Danaher funded the pending deal with a new $5.0 billion 364-day revolving credit facility and a euro bond offering (details under Debt below). The euro notes carried a special mandatory redemption if the Masimo deal had not closed by November 16, 2026.
- June 10, 2026 (closing reported in the Form 10-Q, accession 0000313616-26-000199, and the July 21, 2026 earnings release, accession 0000313616-26-000163): Danaher completed the acquisition, paying cash of approximately $9.8 billion, net of cash acquired. Masimo, which had revenue of about $1.5 billion in 2025, is now part of the Diagnostics segment. The 10-Q records preliminary goodwill of about $4.9 billion and intangible assets of about $5.0 billion. The July release describes the completion as earlier than anticipated.
- The October 21, 2026 release (accession 0000313616-26-000201) shows $84 million (three months) and $130 million (nine months) of acquisition-date inventory fair-value charges excluded from adjusted earnings.
Acquisition of StatLab (closed)
- July 2026, reported in the second quarter earnings release (accession 0000313616-26-000163): Leica Biosystems, Danaher's anatomic pathology business, announced its intention to acquire StatLab, a manufacturer of products across the core histology workflow, from specimen collection through slide staining. The release put StatLab's 2025 revenue at about $250 million.
- September 28, 2026 (closing reported in the Form 10-Q, accession 0000313616-26-000199, Note 2, Subsequent Event Acquisition): Danaher acquired StatLab Medical Products for an aggregate cash purchase price of approximately $1.4 billion, including assumed indebtedness and net of acquired cash, financed with cash on hand. StatLab, described as a provider of pre-analytical consumables and equipment, will be included in the Diagnostics segment from the fourth quarter of 2026.
Earnings and guidance
- October 21, 2026, third quarter 2026 (accession 0000313616-26-000201): revenue of $6.6 billion (up 8.5% as Danaher reports it, rounding to the nearest half point; sales of $6,554 million against $6,053 million); net earnings from continuing operations of $1.2 billion, or $1.71 per diluted share; adjusted diluted EPS of $2.11 (up 11.5%). Non-GAAP core revenue rose 3.0%, or 5.5% excluding respiratory testing. Operating cash flow was $1.9 billion and non-GAAP free cash flow $1.6 billion. GAAP earnings included $263 million of discrete tax benefits, mostly from reserve releases on audit settlements, and a $52 million facility impairment in Biotechnology. Full-year 2026 adjusted EPS guidance was raised to $8.57 to $8.62 from $8.45 to $8.60. Fourth-quarter core revenue excluding respiratory is guided up 4.0% to 5.0%, with respiratory revenue an approximately 150 basis point headwind, for core growth of about 3.0%.
- July 21, 2026, second quarter 2026 (accession 0000313616-26-000163): revenue of $6.3 billion (up 5.5%); net earnings of $870 million, or $1.23 per diluted share; adjusted EPS of $1.94 (up 8.0%); core revenue up 3.0%. Full-year adjusted EPS guidance was raised to $8.45 to $8.60 from $8.35 to $8.55, and full-year core revenue growth was guided to 3.0% to 4.0%. Third-quarter core revenue was guided up 2.0% to 3.0%. The release also described the pending StatLab acquisition (see Acquisition of StatLab above).
- April 21, 2026, first quarter 2026 (accession 0000313616-26-000109): revenue of $6.0 billion (up 3.5%); net earnings of $1.0 billion, or $1.45 per diluted share; adjusted EPS of $2.06 (up 9.5%); core revenue up 0.5%, held back by a light respiratory season at Cepheid. Full-year adjusted EPS guidance was raised to $8.35 to $8.55 from $8.35 to $8.50, with core revenue growth still 3% to 6%.
- January 28, 2026, fourth quarter and full year 2025 (accession 0000313616-26-000004): fourth-quarter revenue of $6.8 billion and adjusted EPS of $2.23; full-year 2025 revenue of $24.6 billion, net earnings of $3.6 billion ($5.03 per diluted share), adjusted EPS of $7.80 and free cash flow of $5.3 billion. Initial 2026 guidance: adjusted EPS of $8.35 to $8.50 and core revenue growth of 3% to 6%.
- January 12, 2026 (accession 0000313616-26-000002): ahead of the J.P. Morgan Healthcare Conference, Danaher said fourth-quarter 2025 revenue would grow in the mid-single digits, with core growth toward the high end of its low-single-digit guide and 2025 adjusted EPS toward the high end of $7.70 to $7.80.
Debt and financing
- April 16, 2026, reported April 17 (accession 0001193125-26-160383): Danaher entered a new $5.0 billion 364-day unsecured revolving credit facility with Bank of America as administrative agent, expiring April 15, 2027, to back its commercial paper program. It carries a leverage covenant of 0.65 to 1.00 or less (Consolidated Leverage Ratio as defined in the agreement). The Form 10-Q states that commercial paper proceeds were used to fund part of the Masimo purchase price.
- April 29, 2026 (accession 0001193125-26-191608): Danaher issued euro senior notes totaling EUR 3.0 billion: EUR 500 million floating rate due 2028, EUR 750 million at 3.250% due 2030, EUR 750 million at 3.625% due 2034 and EUR 1.0 billion at 4.000% due 2038. Net proceeds were about EUR 2.98 billion, earmarked for the cash consideration for Masimo and related costs. The Form 10-Q gives the dollar equivalent of net proceeds as about $3.5 billion.
- June 3, 2026 (accession 0001193125-26-255555): Danaher and its finance subsidiary DH Masi Finance Inc. agreed a private placement of Swiss franc senior notes in seven series (1.65% due 2031 through 2.50% due 2056, maturing June 2031 to June 2056). The Form 10-Q reports a total of CHF 2,383 million and net proceeds of about CHF 2.4 billion, or roughly $3.0 billion, for the Masimo acquisition and general corporate purposes.
Management and board
- August 3, 2026 (accession 0001193125-26-330652): the board appointed Julie Sawyer Montgomery, an Executive Vice President who joined Danaher in 2017 and formerly led Beckman Coulter Diagnostics, as President and CEO effective October 1, 2026, with a seat on the board. Rainer Blair steps down as CEO and director on that date, stays on as Senior Advisor through December 31, 2026 and then consults through March 31, 2027. Her package: $1,500,000 base salary, a target annual incentive of 200% of salary, a 2027 long-term incentive target of $13.2 million, and a $20.0 million stock option award granted August 4, 2026 (50% vesting at four years and 50% at five years). Steven and Mitchell Rales, the co-founders, were also granted special options on 1,000,000 shares each and restricted stock units on 500,000 shares each.
- October 13, 2026 (accession 0000313616-26-000193): each of Steven and Mitchell Rales waived the founder restricted stock units on October 9, 2026 for no consideration. The board was enlarged to thirteen members with the appointment of Daniel Comas, a former Danaher CFO, and Robert Hershberg. Director Alan Spoon will retire at the 2027 annual meeting.
- May 5, 2026, reported May 7 (accession 0000313616-26-000127): shareholders re-elected eleven directors and ratified Ernst & Young as auditor. They also approved an amended Omnibus Incentive Plan that adds 20 million shares and extends the plan term to May 5, 2036.
- February 5, 2026, reported February 10 (accession 0000313616-26-000058): director Jessica Mega retired from the board because of other professional commitments, with no disagreement.
- November 6, 2025 (accession 0000313616-25-000198): director John Schwieters said he would not stand for re-election in 2026, which was to reduce the board from thirteen to twelve.
Closings without a Form 8-K
- Danaher did not file a Form 8-K reporting the closing of the Masimo acquisition (June 10, 2026) or the StatLab acquisition (September 28, 2026); both are reported in the Form 10-Q, accession 0000313616-26-000199.
FAQ · Danaher 8-K filings and events
What has Danaher Corporation (DHR) reported in its recent 8-K filings?
Danaher Corporation (DHR): Form 8-K, October 21, 2026, accession 0000313616-26-000201 (Exhibit 99.1): consolidated condensed statement of earnings for the three and nine months ended September 25, 2026 (with September 26, 2025 comparatives), plus non-GAAP reconciliations and a free cash flow table. No balance sheet or cash flow statement. The release states that the complete financial statements are in the Form 10-Q (accession 0000313616-26-000199).
When does Danaher Corporation (DHR) next file with the SEC?
Danaher Corporation (DHR) is expected to file its next Form 10-K with the SEC on or around February 23, 2027. That date is a projection rather than a company-announced date: it is derived from Danaher Corporation's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q3 FY2026, the period ended 2026-09-25, SEC accession 0000313616-26-000199.
Related companies
How this page was built
This page was built from 15 of Danaher Corporation's own filings with the SEC, read one at a time. Nothing on it is taken from news coverage, analyst commentary or another website. Their accession numbers are cited inline, so any statement here can be traced to the filing it came from and checked against sec.gov.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Danaher Corporation's SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.